Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial

View ORCID ProfileRaburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
doi: https://doi.org/10.1101/2021.12.23.21267374
Raburn Mallory
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raburn Mallory
  • For correspondence: RMallory@novavax.com
Neil Formica
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Pfeiffer
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bethanie Wilkinson
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Marcheschi
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Albert
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather McFall
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Robinson
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce S. Plested
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingzhu Zhu
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane Cloney-Clark
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Zhou
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon Chau
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreana Robertson
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia Maciejewski
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gale Smith
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nita Patel
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory M. Glenn
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filip Dubovsky
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Novavax, Inc
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Article usage

Article usage: December 2021 to May 2022

AbstractFullPdf
Dec 2021492771707
Jan 202231924571101
Feb 202251543301733
Mar 20221332186572
Apr 2022625172338
May 202259238295
Back to top
PreviousNext
Posted December 25, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Raburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
medRxiv 2021.12.23.21267374; doi: https://doi.org/10.1101/2021.12.23.21267374
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Raburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
medRxiv 2021.12.23.21267374; doi: https://doi.org/10.1101/2021.12.23.21267374

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (162)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (862)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8570)
  • Forensic Medicine (4)
  • Gastroenterology (387)
  • Genetic and Genomic Medicine (1756)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1249)
  • Health Policy (622)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (378)
  • Infectious Diseases (except HIV/AIDS) (10316)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (212)
  • Neurology (1680)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (536)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1775)
  • Public and Global Health (3851)
  • Radiology and Imaging (624)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)